Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Moderna: ESMO Answered The Science, Q3 Has To Answer The Money (NASDAQ:MRNA)

Why Moderna remains a Sell: ESMO data, valuation risks, pricing hurdles, and key upcoming catalysts.

Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real question is whether Wall Street is pricing in a cancer breakthrough that has yet to prove itself outside one tumor type.

Moderna's Split Verdict: A Raised Target, a Downgrade, and a Stock Sale Nobody Should Misread

Moderna’s oncology story got a fresh set of numbers last week. Wall Street’s response has been anything but uniform — and that divergence, rather than any single headline, is the more instructive signal for investors trying to work out what the shares are actually worth. The clinical foundation is solid enough. Moderna and Merck published […]